Roles for both cyclic GMP and cyclic AMP in the inhibition of collagen-induced platelet aggregation by nitroprusside

British Journal of Haematology

Volumn 117, Issue 3, 2002, Pages 664-675

  Jang, Elliott K ^a   Azzam, Joseph E ^a   Dickinson, Natalie T ^a   Davidson, Monica M L ^a   Haslam, Richard J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Cyclic AMP; Cyclic GMP; Cyclic GMP dependent protein kinase; Nitroprusside; Platelet

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2',5' DIDEOXYADENOSINE; ACETYLSALICYLIC ACID; BETA PHENYL 1,N 2 ETHENO 8 BROMOGUANOSINE 3',5' CYCLIC MONOPHOSPHOROTHIOTE; COLLAGEN; CYCLIC AMP; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; INDOMETACIN; ISOENZYME; NITROPRUSSIDE SODIUM; PHOSPHOROTHIOIC ACID DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION;

CELLS, CULTURED; COLLAGEN; CYCLIC AMP; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DIDEOXYADENOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NITRIC OXIDE DONORS; NITROPRUSSIDE; PLATELET AGGREGATION;

EID: 0036113619     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03479.x     Document Type: Article

References (48)

1. Adenosine analogs and human platelets: Effects on nucleotide pools and the aggregation phenomenon
2. Interactions between isoprenaline, sodium nitroprusside, and isozyme-selective phosphodiesterase inhibitors on ADP-induced aggregation and cyclic nucleotide levels in human platelets
3. Studies on inhibition of human platelet function by sodium nitroprusside. Kinetic evaluation of the effect on aggregation and cyclic nucleotide content
4. Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside
5. Interactions in platelets between G proteins and the agonists that stimulate phospholipase C and inhibit adenylyl cyclase
6. Analysis of the functional role of cGMP-dependent protein kinase in intact human platelets using a specific activator 8-para-chlorophenylthio-cGMP
7. Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS
8. Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation
9. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase. N-[2-(p-bromocinnamyl-amino) ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells
10. Platelet 5-HT uptake and release stopped rapidly by formaldehyde
11. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: Effects on platelet aggregation
12. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3′,5′-cyclic phosphorothioates
13. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells
14. Inhibition of human platelet adenylate cyclase by collagen fibres. Effect of collagen is additive with that of adrenaline, but interactive with that of thrombin
15. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation
16. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP
17. ADP receptors of platelets and their inhibition
18. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
19. Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets
20. Platelet rap1B phosphorylation is a sensitive marker for the action of cyclic AMP- and cyclic GMP-increasing platelet inhibitors and vasodilators
21. Inhibition of platelet adenylate cyclase by 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor)
22. Cytochalasin B, the blood platelet release reaction and cyclic GMP
23. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets: Evidence for the unidirectional control of platelet function by cyclic AMP
24. Cyclic nucleotides and phosphodiesterases in platelets
25. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition
26. Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries
27. Phosphorylation of the inositol 1,4,5-trisphosphate receptor. Cyclic GMP-dependent protein kinase mediates cAMP and cGMP dependent phosphorylation in the intact rat aorta
28. The interaction of sodium nitroprusside with human endothelial cells and platelets: Nitroprusside and prostacyclin synergistically inhibit platelet function
29. 2+ by cAMP in vascular smooth muscle cells
30. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′,5′-monophosphate kinase I
31. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP
32. Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators
33. cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase
34. 2+ entry in human platelets
35. Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors
36. Structure and function of cGMP-dependent protein kinases
37. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide
38. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium
39. Cyclic GMP-dependent protein kinases: Understanding in vivo functions by gene targeting
40. The activation of expressed cGMP-dependent protein kinase isozymes Iα and Iβ is determined by the different amino-termini
41. Characterization of Sp-5,6-dichloro-β-D-ribofuranosyl-benzimidazole-3′,5′- monophosphorothioate (Sp-5,6-DCl-cBIMPS) as a potent and specific activator of cyclic-AMP-dependent protein kinase in cell extracts and intact cells
42. 3 receptor and cGMP kinase Iβ
43. Autophosphorylation of type Iβ cGMP-dependent protein kinase increases basal catalytic activity and enhances allosteric activation by cGMP or cAMP
44. Cyclic AMP does not inhibit collagen-induced platelet signal transduction
45. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phophospecific monoclonal antibody
46. Photoaffinity labelling of cyclic GMP-binding proteins in human platelets
47. 2 in human platelet-rich plasma
48. Ca channel activity in coronary artery smooth muscle cells